Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Authors: Ye, Jing Christine ^{1, ⁎}, Biran, Noa ², Nair, Sandhya ³, Lin, Xiwu ⁴, Qi, Keqin ⁵, Londhe, Anil ⁵, Ammann, Eric ⁶, Renaud, Thomas ⁷, Kane, Colleen ⁸, Parekh, Trilok ⁹, Gray, Kathleen ⁸, Peterson, Steve ¹⁰, Costa, Luciano J. ¹¹

Source: In Clinical Lymphoma, Myeloma and Leukemia February 2025 25(2):124-134

Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials

Authors: Yong, Kwee ^{a, ⁎}, Einsele, Hermann ^b, Schecter, Jordan M. ^c, Roccia, Tito ^d, Deraedt, William ^e, Lendvai, Nikoletta ^c, Slaughter, Ana ^f, Lonardi, Carolina ^g, Connors, Kaitlyn ^c, Qi, Keqin ^h, Londhe, Anil ^h, Carson, Robin ⁱ, Kharat, Akshay ^j, Cost, Patricia ^d, Valluri, Satish ^d, Mendes, João ^k, Pacaud, Lida ^{l, 1}, Patel, Nitin ^l, Florendo, Erika ^l, Dhakal, Binod ^m

Source: In European Journal of Cancer 17 January 2025 215

Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma

Authors: Mateos, María-Victoria, Chari, Ajai, Usmani, Saad Z., Goldschmidt, Hartmut, Weisel, Katja, Qi, Keqin, Londhe, Anil, Nair, Sandhya, Lin, Xiwu, Pei, Lixia, Ammann, Eric, Kobos, Rachel, Smit, Jennifer, Parekh, Trilok, Marshall, Alexander, Slavcev, Mary, Moreau, Philippe

Source: In Clinical Lymphoma, Myeloma and Leukemia May 2023 23(5):385-393

Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Authors: Siefker-Radtke, Arlene O., Necchi, Andrea, Park, Se Hoon, García-Donas, Jesús, Huddart, Robert A., Burgess, Earle F., Fleming, Mark T., Rezazadeh Kalebasty, Arash, Mellado, Begoña, Varlamov, Sergei, Joshi, Monika, Duran, Ignacio, Tagawa, Scott T., Zakharia, Yousef, Qi, Keqin, Akapame, Sydney, Triantos, Spyros, O'Hagan, Anne, Loriot, Yohann

Source: In European Urology Open Science April 2023 50:1-9

Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer

Authors: Rao, Arpit, Scher, Howard I., De Porre, Peter, Yu, Margaret K., Londhe, Anil, Qi, Keqin, Morris, Michael J., Ryan, Charles

Source: In ESMO Open 2020 5(6)

Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.

Authors: van de Donk, Niels W. C. J., Bahlis, Nizar, Costa, Luciano J., Mateos, María-Victoria, Nooka, Ajay K., Perrot, Aurore, Garfall, Alfred L., Thaman, Pragya, Qi, Keqin, Uhlar, Clarissa, Chastain, Katherine, Doyle, Margaret, Usmani, Saad Z.

Source: Blood Cancer Journal; 10/21/2024, Vol. 14 Issue 1, p1-4, 4p

Subject Terms: MEDICAL personnel, BISPECIFIC antibodies, COVID-19 pandemic, COVID-19, COVID-19 treatment

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study.

Authors: Nooka, Ajay K., Rodriguez, Cesar, Mateos, María Victoria, Manier, Salomon, Chastain, Katherine, Banerjee, Arnob, Kobos, Rachel, Qi, Keqin, Verona, Raluca, Doyle, Margaret, Martin, Thomas G., van de Donk, Niels W. C. J.

Source: Cancer (0008543X); Mar2024, Vol. 130 Issue 6, p886-900, 15p

Subject Terms: PNEUMOCYSTIS jiroveci, MULTIPLE myeloma, PNEUMOCYSTIS pneumonia, BISPECIFIC antibodies, IMMUNOGLOBULIN G, FEBRILE neutropenia

Characteristics and Outcomes in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma Treated with 1-3 Prior Lines of Therapy: Analysis of the Individual Patient-Level Data from Daratumumab Clinical Trials

Authors: Dhakal, Binod, Einsele, Hermann, Schecter, Jordan M, Roccia, Tito ^*, Deraedt, William ^*, Lendvai, Nikoletta ^*, Slaughter, Ana ^*, Lonardi, Carolina ^*, Connors, Kaitlyn ^*, Qi, Keqin ^*, Londhe, Anil ^*, Carson, Robin, Voelker, Jennifer ^*, Cost, Patricia ^*, Valluri, Satish ^*, Florendo, Erika ^*, Pacaud, Lida ^*, Yong, Kwee ^*

Source: In Blood 15 November 2022 140 Supplement 1:4320-4322

Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

Authors: Niemann, Carsten U ^*, Munir, Talha ^*, Moreno, Carol ^*, Owen, Carolyn ^*, Follows, George A ^*, Benjamini, Ohad ^*, Janssens, Ann ^*, Levin, Mark-David, Österborg, Anders ^*, Robak, Tadeusz, Šimkovič, Martin ^*, Voloshin, Sergey ^*, Vorobyev, Vladimir I., Yagci, Munci ^*, Ysebaert, Loic ^*, Qi, Keqin ^*, Qi, Qianaya ^*, Parisi, Lori ^*, Srinivasan, Srimathi ^*, Schuier, Natasha ^*, Baeten, Kurt ^*, Howes, Angela, Bennett Caces, Donne ^*, Kater, Arnon P.

Source: In Blood 15 November 2022 140 Supplement 1:228-230

MM-328 Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: a Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study

Authors: Costa, Luciano J, Bahlis, Nizar J, Usmani, Saad Z, van de Donk, Niels WCJ, Nooka, Ajay K, Perrot, Aurore, Qi, Keqin, Hodin, Caroline, Uhlar, Clarissa, Zuppa, Athena, Chastain, Katherine, Doyle, Margaret, Mateos, María-Victoria

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S546-S547

MM-344 Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)

Authors: van de Donk, Niels WCJ, Garfall, Alfred L, Benboubker, Lotfi, Uttervall, Katarina, Groen, Kaz, Rosiñol, Laura, Matous, Jeffrey V, Vishwamitra, Deeksha, Hodin, Caroline, Stephenson, Tara, Qi, Keqin, Zuppa, Athena, Chastain, Katherine, Mateos, María-Victoria

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S549-S549

Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)

Authors: van de Donk, Niels WCJ, Garfall, Alfred L, Benboubker, Lotfi, Uttervall, Katarina, Groen, Kaz, Rosiñol, Laura, Matous, Jeffrey V, Vishwamitra, Deeksha, Hodin, Caroline, Stephenson, Tara, Qi, Keqin, Zuppa, Athena, Chastain, Katherine, Mateos, María-Victoria

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S236-S236

Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: A Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study

Authors: Costa, Luciano J, Bahlis, Nizar J, Usmani, Saad Z, WCJ van de Donk, Niels, Nooka, Ajay K, Perrot, Aurore, Qi, Keqin, Hodin, Caroline, Uhlar, Clarissa, Zuppa, Athena, Chastain, Katherine, Doyle, Margaret, Mateos, María-Victoria

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S235-S235

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.

Authors: Munir, Talha¹ (AUTHOR) tmunir@nhs.net, Moreno, Carol² (AUTHOR), Owen, Carolyn³ (AUTHOR), Follows, George⁴ (AUTHOR), Benjamini, Ohad⁵ (AUTHOR), Janssens, Ann⁶ (AUTHOR), Levin, Mark-David⁷ (AUTHOR), Osterborg, Anders⁸ (AUTHOR), Robak, Tadeusz⁹ (AUTHOR), Simkovic, Martin¹⁰ (AUTHOR), Stevens, Don¹¹ (AUTHOR), Voloshin, Sergey¹² (AUTHOR), Vorobyev, Vladimir¹³ (AUTHOR), Yagci, Munci¹⁴ (AUTHOR), Ysebaert, Loic¹⁵ (AUTHOR), Qi, Keqin¹⁶ (AUTHOR), Qi, Qianya¹⁷ (AUTHOR), Parisi, Lori¹⁷ (AUTHOR), Srinivasan, Srimathi¹⁸ (AUTHOR), Schuier, Natasha¹⁹ (AUTHOR)

Source: Journal of Clinical Oncology. 7/20/2023, Vol. 41 Issue 21, p3689-3699. 11p.

Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.

Authors: Martin, Peter¹ (AUTHOR) pem9019@med.cornell.edu, Cohen, Jonathon B.² (AUTHOR), Wang, Michael³ (AUTHOR), Kumar, Anita⁴ (AUTHOR), Hill, Brian⁵ (AUTHOR), Villa, Diego⁶ (AUTHOR), Switchenko, Jeffrey M.⁷ (AUTHOR), Kahl, Brad⁸ (AUTHOR), Maddocks, Kami⁹ (AUTHOR), Grover, Natalie S.¹⁰ (AUTHOR), Qi, Keqin¹¹ (AUTHOR), Parisi, Lori¹² (AUTHOR), Daly, Katherine¹² (AUTHOR), Zhu, Angeline¹² (AUTHOR), Salles, Gilles⁴ (AUTHOR)

Source: Journal of Clinical Oncology. 1/20/2023, Vol. 41 Issue 3, p541-554. 14p.

NSP-04 Managing infections, hypogammaglobulinemia, and neutropenia during treatment with teclistamab in relapsed/refractory multiple myeloma: nurse-led experience from the MajesTEC-1 study

Authors: Catamero, Donna, Benito, Patricia Blázquez, Shenoy, Samantha, Chastain, Katherine, Banerjee, Arnob, Qi, Keqin, Skerget, Sheri, Doyle, Margaret, Kruyswijk, Sandy

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 2:S315-S315

P-328 Talquetamab vs real-world physician's choice of therapy (RWPC): comparative efficacy in patients (pts) with triple-class exposed (TCE) relapsed/ refractory multiple myeloma (RRMM)

Authors: Ye, Jing Christine, Biran, Noa, Nair, Sandhya, Lin, Xiwu, Qi, Keqin, Londhe, Anil, Ammann, Eric, Renaud, Thomas, Kane, Colleen, Parekh, Trilok, Gray, Kathleen, Peterson, Steve, Costa, Luciano

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 2:S219-S220

OA-51 Preliminary recommendations for prevention and management of infections, hypogammaglobulinemia, and neutropenia during treatment with teclistamab based on experience from the MajesTEC-1 study

Authors: van de Donk, Niels, Nooka, Ajay, Rodriguez, Cesar, Mateos, Maria-Victoria, Chastain, Katherine, Banerjee, Arnob, Kobos, Rachel, Qi, Keqin, Verona, Raluca, Doyle, Margaret, Martin, Thomas, Manier, Salomon

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 2:S32-S32

MM-192 Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study

Authors: Manier, Salomon, Nooka, Ajay, Rodriguez, Cesar, Mateos, Maria-Victoria, Chastain, Katherine, Banerjee, Arnob, Kobos, Rachel, Qi, Keqin, Verona, Raluca, Doyle, Margaret, Martin, Thomas, van de Donk, Niels

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S480-S481

MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study

Authors: Usmani, Saad Z, Karlin, Lionel, Benboubker, Lotfi, Nahi, Hareth, San-Miguel, Jesús, Trancucci, Danielle, Qi, Keqin, Stephenson, Tara, Puchalt, Alfredo Perales, Chastain, Katherine, Chari, Ajai

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S477-S477